Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype
Journal article, 2020
Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) reduces the risk of relapse in the post-chemotherapy phase of acute myeloid leukemia (AML). Here we report the results of exploratory analyses of the clinical efficacy of HDC/IL-2 in AML with focus on the impact of karyotype aberrations in leukemic cells. Post-hoc analyses of phase III trial data suggested that HDC/IL-2 is primarily beneficial for patients with AML of normal karyotype. These results may be helpful in the selection of patients who are suitable for therapy and in the design of future immunotherapy protocols aiming at further defining the mechanism of relapse prevention by HDC/IL-2.
Acute myeloid leukemia
immunotherapy
IL-2
relapse prevention
histamine dihydrochloride
normal karyotype
Author
Malin S. Nilsson
University of Gothenburg
Alexander Hallner
University of Gothenburg
Mats Brune
University of Gothenburg
Staffan Nilsson
University of Gothenburg
Chalmers, Mathematical Sciences, Applied Mathematics and Statistics
Fredrik B Thorén
University of Gothenburg
Anna Martner
University of Gothenburg
Kristoffer Hellstrand
University of Gothenburg
Human Vaccines and Immunotherapeutics
2164-5515 (ISSN) 2164-554X (eISSN)
Vol. 16 1 109-111Subject Categories
Immunology in the medical area
Medical Biotechnology (with a focus on Cell Biology (including Stem Cell Biology), Molecular Biology, Microbiology, Biochemistry or Biopharmacy)
Microbiology in the medical area
DOI
10.1080/21645515.2019.1636598
PubMed
31242079